Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Moodys
Accenture
Healthtrust
Mallinckrodt
Cipla
Fuji
Farmers Insurance
Cerilliant

Generated: January 21, 2019

DrugPatentWatch Database Preview

Glaxosmithkline Cons Company Profile

« Back to Dashboard

Summary for Glaxosmithkline Cons
International Patents:315
US Patents:11
Tradenames:11
Ingredients:10
NDAs:15

Drugs and US Patents for Glaxosmithkline Cons

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 8,147,461 ➤ Try a Free Trial Y ➤ Try a Free Trial
Glaxosmithkline Cons NICORETTE nicotine polacrilex TROCHE/LOZENGE;ORAL 021330-001 Oct 31, 2002 OTC Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons PREVACID 24 HR lansoprazole CAPSULE, DELAYED REL PELLETS;ORAL 022327-001 May 18, 2009 OTC Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 OTC Yes Yes 7,541,350 ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Glaxosmithkline Cons

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 4,943,565 ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL terbinafine hydrochloride SOLUTION;TOPICAL 020749-001 Oct 17, 1997 4,755,534*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SOLUTION;TOPICAL 021124-001 Mar 17, 2000 5,681,849*PED ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine GEL;TOPICAL 021958-001 Jul 24, 2006 5,856,355*PED ➤ Try a Free Trial
Glaxosmithkline Cons ALLI orlistat CAPSULE;ORAL 021887-001 Feb 7, 2007 4,598,089 ➤ Try a Free Trial
Glaxosmithkline Cons LAMISIL AT terbinafine hydrochloride SPRAY;TOPICAL 021124-002 Mar 17, 2000 6,121,314*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GLAXOSMITHKLINE CONS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 60 mg ➤ Subscribe 2010-09-08
➤ Subscribe Gum 4 mg ➤ Subscribe 2013-01-22
➤ Subscribe Gum 2 mg ➤ Subscribe 2013-01-22

International Patents for Glaxosmithkline Cons Drugs

Country Document Number Estimated Expiration
South Korea 20050004845 ➤ Try a Free Trial
Denmark 1305329 ➤ Try a Free Trial
Slovenia 1775305 ➤ Try a Free Trial
Japan 2007528248 ➤ Try a Free Trial
European Patent Office 1699512 ➤ Try a Free Trial
European Patent Office 1471884 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Glaxosmithkline Cons Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
6 Finland ➤ Try a Free Trial
C0014 France ➤ Try a Free Trial PRODUCT NAME: FLUTICASONE FLUORATE; REG. NO/DATE: EU/1/07/434/001 20080111
C/GB98/044 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ORLISTAT; REGISTERED: UK EU/1/98/071/001 19980729; UK EU/1/98/071/002 19980729; UK EU/1/98/071/003 19980729; UK EO/1/98/071/004 19980729; UK EU/1/98/071/005 19980729; UK EU/1/98/071/006 19980729
2008000029 Germany ➤ Try a Free Trial PRODUCT NAME: FLUTICASONFUROAT UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/07/434/001-003 20080111
C0021 Belgium ➤ Try a Free Trial PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
0343 Netherlands ➤ Try a Free Trial 300343, 20210803, EXPIRES: 20230110
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Dow
Covington
Cantor Fitzgerald
Moodys
Argus Health
Colorcon
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.